Inflammation, Cancer and Chemoresistance: Taking Advantage of the Toll-Like Receptor Signaling Pathway
Article first published online: 8 JAN 2007
American Journal of Reproductive Immunology
Volume 57, Issue 2, pages 93–107, February 2007
How to Cite
Chen, R., Alvero, A. B., Silasi, D.-A. and Mor, G. (2007), Inflammation, Cancer and Chemoresistance: Taking Advantage of the Toll-Like Receptor Signaling Pathway. American Journal of Reproductive Immunology, 57: 93–107. doi: 10.1111/j.1600-0897.2006.00441.x
- Issue published online: 8 JAN 2007
- Article first published online: 8 JAN 2007
- Submitted September 13, 2006; accepted October 6, 2006.
- epithelial ovarian cancer;
- Toll-like receptor
The association between chronic inflammation and cancer has long been observed. Furthermore, NF-κB activation and the subsequent production of cytokines, chemokines, growth factors, and antiapoptotic proteins has been found to be involved in cancer progression and chemoresistance. However, the signals inducing NF-κB in cancer cells are still not well understood. Here, we reviewed the association between chronic inflammation and cancer, the role of NF-κB and its inhibitors as potential anticancer drugs, and Toll-like receptors as possible signal initiators for NF-κB activation and inflammation-induced carcinogenesis and chemoresistance. Furthermore, we propose that, the stimulation of Toll-like receptors by microbial components and/or endogenous ligands may represent the initial signal promoting a proinflammatory environment that will enhance tumor growth and chemoresistance.